e-LEA3D: a computational-aided drug design web server by Douguet, Dominique
e-LEA3D: a computational-aided drug
design web server
Dominique Douguet*
CNRS UMR6097 – Universite ´ Nice – Sophia Antipolis 660, route des lucioles 06560 Valbonne, France
Received February 10, 2010; Revised April 13, 2010; Accepted April 17, 2010
ABSTRACT
e-LEA3D web server integrates three complemen-
tary tools to perform computer-aided drug design
based on molecular fragments. In drug discovery
projects, there is a considerable interest in identify-
ing novel and diverse molecular scaffolds to
enhance chances of success. The de novo drug
design tool is used to invent new ligands to
optimize a user-specified scoring function. The
composite scoring function includes both structure-
and ligand-based evaluations. The de novo
approach is an alternative to a blind virtual
screening of large compound collections. A heuris-
tic based on a genetic algorithm rapidly finds which
fragments or combination of fragments fit a QSAR
model or the binding site of a protein. While the
approach is ideally suited for scaffold-hopping,
this module also allows a scan for possible substitu-
ents to a user-specified scaffold. The second tool
offers a traditional virtual screening and filtering of
an uploaded library of compounds. The third module
addresses the combinatorial library design that is
based on a user-drawn scaffold and reactants
coming, for example, from a chemical supplier.
The e-LEA3D server is available at: http://bioinfo
.ipmc.cnrs.fr/lea.html.
INTRODUCTION
Computer-aided drug design methods contribute to the
early stage of the drug discovery process to identify new
bioactive molecules. Computational methods comprise
virtual screening of available chemical databases and
de novo drug design. The two approaches aim to select a
set of molecules that are predicted to exhibit a biological
activity on a given target. The estimation of the activity,
usually by the mean of a score, is addressed by various
ligand- and structure-based methods depending on the
data on known ligands and the availability of the 3D ex-
perimental structure of the target.
Contrary to virtual screenings used to mine in-house
and commercial collections, de novo drug design can
create molecules that do not exist in known compound
databases. De novo design methods are automated com-
putational procedures that build molecules by using atoms
or fragments with the aim that the resulting molecular
structures would ﬁt speciﬁed property constraints. They
allow the exploration of the theoretically available
chemical space, a space larger than that can be
enumerated by synthesis (1,2) or even by computer. For
example, Blum and Reymond propose a list of small
organic molecules containing up to 13 atoms of C, N,
O, S and Cl. The public database GDB-13 contains
970million of druglike molecules (3). Nevertheless, the
virtual screening of millions of compounds using
docking software, for example, is still time consuming
even with high-throughput methods. On the contrary,
alternative approaches as de novo drug design use search
strategies to eﬃciently explore the chemical space without
a fully enumeration. Particle Swarm Optimization (4) or
Evolutionary Algorithms (5), analogous to Genetic
Algorithms (6–9), are examples of heuristics employed
for this purpose. The main downside of this strategy is
that it can generate compounds that are promising but
diﬃcult to synthesize (10). To overcome this defect, the
designed compounds can alternatively be used as a query
in a structural similarity search in commercial collections
[e.g. ZINC, http://zinc.docking.org/choose.shtml (11)].
Thus, it is possible to select a small- and focused-library
of available analogs that can be further evaluated by a
virtual screening step and eventually tested experimentally
(12). Likewise, de novo drug design approach has the
property to suggest new scaﬀold candidates. In this case,
synthetic chemistry experts may help in deﬁning a synthet-
ic route and in selecting possible reactants to create a
combinatorial library (13). For example, van Hoorn and
Bell designed a Bayesian Idea Generator to identify the
likely chemistry protocols associated with a given
compound (14).
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portant strategy in drug discovery. This may be achieved
by a traditional chemistry synthesis but also, in some par-
ticular cases, by a target-guided synthesis (TGS) also
called in situ click chemistry (15). TGS lets the
protein-binding site to select ﬁttest reagents to form
highly potent ligands. For example, Kolb and co-workers
discovered new inhibitors for the acetylcholinesterase
(AChE) and the carbonic anhydrase II from a (1,3)-
dipolar cycloaddition between azides and acetylenes react-
ants (16–18). This type of approach uses multireagent
mixtures whose complexity in terms of components must
be limited to avoid aggregation and product identiﬁcation
problems. A virtual screening may help to prioritize the
most promising ones when hundreds of reagents are com-
mercially available.
Historically, computational tools have been developed
inside companies by modeling teams or by modeling
software companies (19,20). Various innovative tools
have also been developed by academics but their acquisi-
tion by software companies often limited their use for free
by this community. As a result, the number of ‘free of
charge’ databases and softwares dedicated to
cheminformatic is scarce. The CCL computational chem-
istry provides downloadable software packages, for
example, the de novo drug design program NEWLEAD
(21) (http://www.ccl.net/cca/software/MAC/newlead_
linux_and_mac_osx/). In the same manner, there is
a relative few number of web resources dedicated
to small molecules compared to other categories
(http://bioinformatics.ca/links_directory/). For example,
a tremendous number of bioinformatic tools have been
created and provided to the entire scientiﬁc community
to respond to an increasing need in terms of sequence
analyses and structure predictions. Few years ago,
Villoutreix et al. cataloged a list of resources ranging
from homology modeling to protein docking and virtual
screening (http://www.vls3d.com/links.html) (22).
However, only a minority of chemistry-oriented tools is
true on line facility and thus the others are not easily prac-
ticable for non-expert scientists. Among web servers, some
are dedicated to the virtual screening by docking: DOCK
Blaster (http://blaster.docking.org/start.shtml) (23),
TarFisDock (http://www.dddc.ac.cn/tarﬁsdock/) (24)
or the SCFBIO server (http://www.scfbio-iitd.res
.in/bioinformatics/drugdesign.htm), but they only screen
existing, commercial or uploaded, libraries of molecules.
This prompts us to develop a cheminformatic web server
also able to create and build small molecules.
Herein, we present e-LEA3D, the ﬁrst web server to
perform computer-aided de novo drug design, to build
focused combinatorial libraries of molecules and to
perform virtual screenings. The interplay between these
approaches is described in Figure 1. The de novo drug
design tool creates new molecules by using a genetic algo-
rithm to evolve a population of molecules which are grad-
ually improved by competing for the ‘survival of the
ﬁttest’ (25). Here, a molecule results from the association
of various 3D fragments extracted from known bioactives
compounds. The second tool assists the user in the design
of a combinatorial library where a central core is con-
nected to reactants coming, for example, from a
supplier. The reactants are modiﬁed according to the
user speciﬁcations in order to extract the substituent
part only. The generated virtual library can be automat-
ically evaluated by using the same scoring function as the
one used in the de novo drug design step. It aims to pri-
oritize the reactants.
CONCEPTS AND METHODS
De novo drug design
The de novo drug design module is based on a new version
of the LEA3D engine (25). This program creates new
molecules either from scratch or based on a user-deﬁned
scaﬀold on which substituents have to be optimized.
De novo Drug Design
Database Screening
Combinatorial Library Design
Composite Scoring Function
Results html page
sdf database
Drawing the scaffold + sdf reactant library
invents molecules
uploads user’s molecules
builds user’s molecules
virtual screening
Figure 1. Interplay between the three e-LEA3D modules.
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genetic algorithm to optimize the combination of frag-
ments. The algorithm dynamically evolves a population
of molecules through their modiﬁcations by mutation
and crossover operators. The reproduction is ﬁtness-
proportionate to favor best candidate molecules for
breeding. At each iteration, a new population of molecules
replaces the parents except the best one to comply with the
elitism strategy. This prevents the best solution from being
lost and allows a relative high percentage of mutations
(70%) compared to the crossover one (30%). The
mutation operators bring diversity by integrating new
fragments in molecules while the crossover operator re-
combines fragments already present in the current popu-
lation. During a crossover, two parent molecules
interchange a portion of their structures. To mutate mol-
ecules, four operators have been created: the suppression
of one fragment, the addition or the replacement of one
fragment by a new one coming from the fragment
database and the permutation or scrambling of fragments
of the parent structure. A more detailed description can be
found in a previous publication (25). The current version
of LEA3D diﬀers from the published one in its way to
store the fragments, to represent the molecule and to
display the results. Also, it uses diﬀerent docking
program: PLANTS (26) instead of FlexX (27) but the
genetic algorithm and its parameters are unchanged.
The current building blocks, rings and acyclic frag-
ments, have been extracted from approved and investiga-
tional drugs identiﬁed by a USAN (Comprehensive
Medicinal Chemistry, Symyx Solutions, Inc.). The
fragment database contains 5283 building blocks; only
13% of the disconnected fragments were unique. Each
fragment possesses one or more ‘X’ dummy atoms that
memorize the original substitution pattern of the
fragment as well as the stereochemistry. If a fragment
contains several substitution sites, one of them is
randomly selected to be connected. Eventually, the 3D
conformation of the created molecule is generated by the
program Frog (28).
Then, the ﬁtness of each molecule is evaluated via a
function which takes as input the molecular structure
and returns a numeric score. The evaluation can integrate
a selected number of molecular properties and/or a
protein–ligand docking score calculated by the program
PLANTS (26). The user can deﬁne the relative importance
of each individual property by assigning it a weight.
Ligand-based properties include descriptors commonly
used to deﬁne the boundaries of the lead-like and
drug-like chemical space. The range limits are given for
some of them along with a publication reference (molecu-
lar weight, Logp, number of atoms, number of h-donors
and h-acceptors, polar solvent accessible surface area, mo-
lecular refractivity, moment of inertia, rotatable bonds,
number of rings and number of aromatic rings).
Additional molecular properties are the search of
chemical functions, the deﬁnition of a pharmacophore
and the ligand similarity measure based on a molecular
ﬁngerprint. The ﬁngerprint consists of a vector of 120
cells, each cell indicating the presence or the absence of
the associated atom type calculated following the deﬁn-
ition of Ghose (29,30).
In general, LEA3D produces diﬀerent solutions at each
run since it uses a heuristic and randomly selects frag-
ments and their substitution sites, excepting when it
must deduce a chemical structure with descriptor values
identical to those of a given target compound. For
example, to deduce the structure of the protonated form
of aspirin, one uses the following properties: a molecular
weight equals to 180, a number of heavy atoms equals to
13, a number of aromatic rings equals to 1 and the
presence of the chemical functions ester and acid. In
such case, diﬀerent runs converge toward analogs
(score100%) or ﬁnd the target solution (score=100%).
Finally, e-LEA3D can be set to maintain the presence of
one particular fragment or scaﬀold through the evolution-
ary process. Subsequently, molecules are evolved by
adding one or more substituents to this scaﬀold at
chosen positions. This strategy is advantageous when the
docking program, for example FlexX (27), is able to
superimpose the conserved building block with a structure
whose coordinates in the binding site are known by X-ray
crystallography (25); the docking procedure is accelerated.
Combinatorial library builder
Since the 1990s, the experimental combinatorial chemistry
and the computational design form a partnership to focus
the synthesized collections toward a speciﬁed family target
and to optimize the ADME characteristics (31). A key
feature in e-LEA3D is the possibility to deﬁne a speciﬁc
scaﬀold as the central core of a combinatorial library. This
has been developed to deal with simple cases of library
design where a ﬁnal scaﬀold is common to all products.
Note that this module does not allow reaction-based spe-
ciﬁcations such as a rearrangement of the central core or
of the reactants. To fully exploit this module, a minimal
expertise in chemistry is required. To design a library, the
user simply draws a scaﬀold and uploads the reactant ﬁle.
The procedure is iterative and several substituents may be
added to the scaﬀold. For this purpose, reactants coming,
for example, from a chemical supplier are modiﬁed ac-
cording to the user speciﬁcations in order to extract the
substituent part only. Then, substituents are connected to
the scaﬀold at the selected position. Once created, the
library can be evaluated by a composite scoring function
(described in the previous section) and thereby, the most
promising reagents are prioritized. A tutorial to build an
azide/acetylene library is present on our web server. This is
a reaction well-suited for the in situ click chemistry
(http://bioinfo.ipmc.cnrs.fr/images/tutorial_combinatorial
_library.pdf).
WEB SERVER
In both modules, a two steps procedure is required to
launch the task. First, the user uploads the input data
whose integrity is checked by the server and then, the
user is invited to complete the request. Once the run is
submitted, a transition page gives a link to the result
web page. We encourage the bookmarking of the link.
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drug design (6h) and the virtual screening of more than
50 molecules are scheduled by the queuing system Torque.
Other tasks may also take long times in case where there
are several users employing the web service but usually,
they takes few seconds or minutes. The results are stored
on the server for 20 days. Tools such as the ACD structure
drawing Applet (v.1.30), the Chemis3D (v2.89a) and JMol
(v11.6.13) applets allow sketching small molecules and
visualizing them at the diﬀerent steps (input and output).
De novo drug design server
Input. In the front-page, the user is invited to create its
composite scoring function by selecting at least one
property. Each selected ligand-based property is deﬁned
by a minimal and/or maximal value and a weight. A
guideline at the bottom of the page explains how to set
an exact value or a range of values. Most of the present
molecular properties have been used and referenced in the
literature to deﬁne the limits of an appropriate chemical
space. In such cases, default values have been set.
Additionally, three other ligand-based properties comple-
ment the list: the identiﬁcation of mandatory chemical
characteristics such as chemical functions, the identiﬁca-
tion of a pharmacophore and a similarity measure based
on a ﬁngerprint. In the last case, the similarity between a
candidate and a reference molecule is calculated
by comparing their atom type compositions calculated
following the deﬁnition of Ghose and Crippen (GC de-
scriptors) (30).
If the structure-based property is integrated in the
function score, it is necessary to upload the protein struc-
ture in mol2 format [input for PLANTS (26)]. This format
is correctly generated if the protein is protonated. As crys-
tallographic ﬁles from the Protein Data Bank do not
contain hydrogen atoms, it is necessary to convert the
PDB input ﬁle into a protonated pdb ﬁle by using
the PDB2PQR web server (see the help section at the
bottom of the front-page) (32). The generated pdb ﬁle is
suitable to be uploaded by e-LEA3D in order to be con-
verted into a mol2 ﬁle format. Finally, it is required to
deﬁne the binding site by indicating either the name, the
number and the chain name of one residue, for example
the ligand, present in the pocket or the coordinates of the
center of it. The binding site is centered on the last and
includes residues whose at least one atom belongs to the
sphere of the chosen radius (the default one is 10A ˚ ).
Once the checking step completes, a web page summar-
izes the scoring function content. At this stage, two add-
itional parameters can be set to generate conformers and
to perform the ionization of carboxylate, phosphate,
amidinium and guanidinium groups. The default settings
activate the generation of one conformer and accept the
ionization step. Then, the user can either screen a library
of molecules (‘Database screening’ button on the right) or
start the ‘De novo Drug Design’ program on the left. The
‘Database screening’ option needs to upload a sdf ﬁle of
the molecules to screen. An option enables to ﬁlter out
unﬁtted molecules (i.e. having a score <100%). This
option is omitted when the docking is a part of the
scoring function. In the ‘De novo Drug Design’ program,
most of the parameters are already deﬁned but it is
possible to modify the population size and the number
of generations. Note that changing these parameters is
not recommended as it can drastically increase the
time-cost of the drug design process. An advanced
option allows selecting a mandatory scaﬀold/fragment in
sdf format that must be present in each generated
molecule. This option is useful when the objective is to
search new substituents or to growth a fragment known
to bind the protein target.
The computational procedure ﬁlters out candidate mol-
ecules that have not 80% of the molecular properties when
structure- and molecular-based properties are selected.
Indeed, the docking step and the 3D conformation gener-
ation are the most time consuming tasks. Therefore, it is
recommended to associate the docking function with an
upper limit for the molecular weight (MW500 for
example).
Output. The Figure 2 presents an example of the output
page resulting from the automated de novo drug design of
ligands targeting the retinoic acid receptor RXRa and
having a benzoic acid as a mandatory fragment. The
right panel of the web page is updated every minute to
follow the design over the generations. Each row summar-
izes the features of the best candidate of the generation:
the generation number, the rank, the score in percentage
(the maximum is 100%), the molecular properties of the
selected conformer, the fragment composition and the
number of the best conformer. The left panel displays
the molecule in 3D alone or in complex with a binding
site if the scoring function includes a docking score. A
click on the molecule name at the right panel executes
the display at the left window. Molecules and complexes
are also downloadable in sdf, mol2 and pdb ﬁle format,
respectively. If several conformers have been generated for
one molecule, the sdf ﬁle contains the coordinates of the
best one whereas the mol2 ﬁle contains its docking pose
conformation. There is also a link at the top of the right
page to download the concatenated sdf ﬁle of the best
candidates. Once the run completes, two links give
access to the convergence plot of the genetic algorithm
for the mean score and for the best score.
Combinatorial library builder server
Input. The user is guided step by step to deﬁne the
building blocks of the combinatorial library. First, the
ﬁnal scaﬀold is drawn by using the ACD structure
drawing Applet. Then, it must be converted into a text
ﬁle by the button ‘Click to Convert’ and submitted to a
3D conversion. Note that the positions of the future sub-
stituents are linked to a hydrogen atom. The result web
page displays the sketch of the central core with its
formula, molecular weight and a link to download the
sdf ﬁle. The Chemis3D applet displays the fragment and
the numbering of the atoms and thus it enables to identify
the number of the heavy atom that will be substituted. A
ﬁeld is allocated to store this number. Then, the user
uploads the reagent ﬁle in sdf format. The reagent
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an amine, a thiol, a bromine atom ...The next step aims
to deﬁne where to break a single bond to extract the sub-
stituent part. Two cases may occur. The ﬁrst case allows
identifying the atom type to be replaced by the ﬁnal
scaﬀold. Additional information about the neighbor
atoms may help to select the right site and the ‘keep’
comment indicates which fragment of the two discon-
nected parts is the substituent. The second case has been
created to deal with reagents whose atom to be replaced
may be ambiguous like a hydrogen atom for example. To
localize the appropriate hydrogen, the user must deﬁne an
unambiguous neighbor, for example, a sulfur atom con-
nected to the hydrogen to replace. This neighbor atom can
be further described by its bonded neighbors and the
comment ‘keep’ is recommended to ﬂag the desirable
part. For each case, an example is displayed at the right
side of the ﬁeld. Finally, a checkbox oﬀers the option to
generate a conformer for each combined molecule but this
option must not be selected if the user plans to add
another substituent because the order of the atoms in
the sdf ﬁle is scrambled by the 3D generator program.
Output. The output web page presents four parts from (A)
to (C.2). The ﬁrst section summarizes the reagent modiﬁ-
cations by visualizing the ﬁrst reagent of the upload ﬁle
and the ﬁrst modiﬁed reagent. The ‘X’ atom in pink in
the Chemis3D display is replaced by the ﬁnal scaﬀold. The
accepted reagent ﬁle is downloadable in sdf format. The
second section (B) provides a link to the result web page
similar to that one generated by the de novo drug design
server. Each combined molecule is visualized by the Jmol
output
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rec_3H0A_pqr.pdb: #Conformer
PLANTS_score
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(download pdb complex)
(download mol2)
1 -84.590 -84.590
(4.97)
10 1 81.56 mm 1*6-2*4 g10_mol1.sdf 1
conformers
(download sdf) 357 0 758
Best is no
1 rec_3H0A_pqr.pdb: #Conformer
PLANTS_score
rec_3H0A_pqr.pdb
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Figure 2. Input and Output contents of the de novo drug design module. Inputs are the structure of the RXRa nuclear receptor and the building
block ‘benzoic acid’, a substructure of the approved drug bexarotene present in the crystallized structure (residue name 9RA; the picture has been
produced using PyMOL). The composite scoring function includes a docking by the program PLANTS in the RXRa binding site and a calculation
of the molecular weight that must be 469. Outputs are: (a) the follow-up of the ﬁttest molecule of each generation. Only the ﬁrst and the last
generation are presented. The score in percentage is displayed (81.56% for the best candidate) as well as its composition: the PLANTS score (–94.67)
and the molecular weight (357). A second score in parenthesis, the Xscore (37), evaluates the docking pose from PLANTS (9.07). The molecular
composition and the conformer number are given. The best candidate is a combination of the building block ‘benzoic acid’ (lego 0) with the lego
number 758. The ﬁrst building block (lego 0) is connected by its atom number 6 (coded by 1*6) with the second building block (lego 758) by its atom
number 4 (2*4). (b) A click on the ﬁle name in blue displays the molecule in the java applet Jmol. The backbone of the active site is depicted in cyan
and the side chains of basic residues are colored in blue. The side chain of the ARG316 is involved in an ionic bond with the carboxylate of the
ligand whose carbons are colored in grey and oxygens in red. (c) The superimposition of the de novo candidate in blue on the co-crystallized drug
bexarotene in green. The benzoic acid groups are perfectly superimposed.
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either evaluated by a scoring function or modiﬁed by
adding another reagent. In the (C.1) section, a link
heads to the front-page of the ‘de novo drug design or
screen’ module. Once the scoring function is built, the
‘Database screening’ module automatically gets the com-
binatorial library as the database to screen. The result web
page presents the same features as in (B). In addition, it
recapitulates the sdf datablock of the reagents in the mo-
lecular properties column when it exists in the original ﬁle.
This is useful to identify the reagents by their supplier
identiﬁers. In the (C.2) section, the user can iterate the
addition of another reagent. It produces a result page
with the same features as the present one.
CONCLUSIONS
We presented e-LEA3D, a server that aims to invent ideas
of ligands (scaﬀold-hopping), to screen/dock user’s mol-
ecules into the structure of the target protein and to assist
scientists in the optimization of hits by the creation of a
focused combinatorial library of molecules. The discovery
of new potent ligands remains crucial for a large spectrum
of applications and topics as pharmacological tools for
in vitro and in vivo physiophatologic studies. This server
complements other services dedicated to small molecules
and which are presented in a pipeline manner: PharmaGist
for a pharmacophore detection based on aligned ligands
(33), Superimpose ´ for a 3D similarity search of known
ligands (34), wwLigCSRre for a similarity search in com-
mercial databases (35) and FAF-Drugs for the ADME/
tox ﬁltering of candidates (36). In the near future, we plan
an upgrade of the ‘Database screening’ module where we
will oﬀer the selection of several focused databases to
screen approved drugs and commercial subdrugs of
drugs suitable, for example, to start a fragment-based
drug discovery program.
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